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 The efficacy of radical radiotherapy for patients with primarily diagnosed 
prostate cancer with metastases to regional lymph nodes
Tomasz Krzysztofiak1, Wojciech Majewski2
Objectives . Retrospective analysis of 22 patients with high risk prostate cancer and clinical regional lymph node 
involvement treated with radical radiotherapy and ADT.
Material and methods . The mean pre-treatment PSA level was 69 ng/ml. Median age — 65 years. Lymph nodes 
involvement was determined by radiological imaging. Duration of ADT was 2–3  years. All patients underwent co-
nventional radiotherapy. Dose to the prostate ranged from 75.6 to 78 Gy, to elective lymph nodes — 44 to 50 Gy, 
boost dose to involved lymph nodes — 60 to 75,6 Gy. Median follow-up was 40 months.
Results . The 3-year and prognosed 5-year bCR in studied group was 78% and 65%. The 3-years and 5-years progno-
sed OS was 88% and 73%. We observed 5 failures. No relapse in a nodal boost region was observed. No dose-effect 
relationship was observed for bCR nor OS. Only T stage proved prognostic for bCR.
Conclusions . The results showed good outcome for node positive prostate cancer patients treated with radical in-
tent. No dose-effect relationship suggest that metastatic pelvic lymph nodes may not require such dose escalation 
as primary tumor. 
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Introduction
Prostate cancer is the second most common cancer 
diagnosed among men in Poland. Every year over 14 000 
new cases are diagnosed, which is due in part to the aging 
of the population. Thanks to screening, modern diagnostic 
and therapeutic methods, it is often detected at an early 
stage and despite an increase in morbidity, the mortality rate 
remains constant [1]. While patients with low-risk disease 
have a very good prognosis, patients with locally or locore-
gionally advanced prostate cancer pose a major challenge 
in contemporary urological oncology.
Among patients with prostate cancer, the group in 
which the optimal treatment is not clearly established, are 
patients with metastases in regional lymph nodes [2]. These 
patients are stratified as “regionally advanced” by NCCN [3]. 
In this case, hormonal therapy based on full androgen de-
privation is a widely-recognized method of treatment [3–5]. 
However, if isolated, single or minor, regional node involve-
ment have been determined, a radical treatment may be 
considered, although there is no straightforward evidence 
of the superiority of such method over palliative treatment. 
No randomized trial has undertaken this topic. Hormonal 
therapy is not radical approach, which is why different me-
dical centers, depending on their own experience, include 
radiotherapy or surgery in the form of prostatectomy with 
lymphadenectomy [6]. Such treatment may seem justified 
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even for oligometastatic disease [7], which is why it can be 
considered in the case of isolated lymph node metastases.
Material and methods
The subject of this study is to present the results of 
patients’ treatment with conventionally fractionated radio-
therapy along with hormonotherapy at the Maria Skłodows-
ka-Curie Institute — Oncology Center, Branch in Gliwice in 
the years 2008–2014, in patients with prostate cancer with 
clinically diagnosed regional lymph node involvement eli-
gible for radical treatment. 
The study group included 22 consecutive patients with 
prostate cancer destined for primary radical radiotherapy 
with clinically diagnosed regional lymph node metastases 
(N+) who were treated in the years 2008–2014. Only patients 
treated with conventionally fractionated radiotherapy were 
included in the analysis. An alternative way of treatment for 
patients with N+ in our center, which has been implemented 
gradually since 2012, was a stereotactic boost with the use 
of the CyberKnife method after the completion of conven-
tionally fractionated radiotherapy. Patients treated in this 
way were not included in the analysis.
The decision regarding radical radiotherapy in patients 
with metastatic diagnosis in regional lymph nodes was arbi-
trarily based on physical examination, patient’s medical hi-
story and imaging studies with regard to expected survival.
To asses the primary disease, each patient had a PSA test, 
along with TRUS, abdominal and pelvic computer tomography, 
chest x-ray and bone scintigraphy. The presence of metastases 
in regional lymph nodes was assessed clinically, i.e. based on 
imaging studies of CT, MRI (17 cases) or PET-CT (5 cases). No 
surgical procedures (lymphangectomy) have been performed 
to confirm the presence of metastases. The AJCC 2002 classifi-
cation system was used to assess the stage of TNM.
Regional lymph nodes were defined as pelvic lymph 
nodes up to common iliac lymph nodes (N1–N3). Nodes 
above the aortic bifurcation were considered as distant 
metastases. Patients diagnosed with oligometastatic disease 
(M+) treated radically were not included in the study. No 
patient from the study group was diagnosed with distant 
metastases before radiotherapy.
The median age was 65 (+/- SD 8 years) and ranged from 42 
to 81 years. The PSA level in the blood before treatment ranged 
from 7.1 to 247.5 ng/ml (with an average value of 69 ng/ml).
All patients were subject to neoadjuvant hormonal 
therapy before radiotherapy. The duration of neoadjuvant 
hormonal therapy ranged from 2 to 18 months and avera-
ged 7 months. In 18 patients, total androgen deprivation 
was used, in 2 patients — LH-RH analogue alone, and in 
the next two patients — antiandrogen. All patients, except 
two, had continued hormonal therapy after radiotherapy 
for a period of 2–3 years, and in the event of a recurrence, 
hormonal therapy was introduced permanently. Clinical cha-
racteristics of the study group are presented in Table I. Highly 
differentiated prostate cancer without a Gleason score was 
reported in 2 patients who were classified as Gleason 3+3. 
Radiotherapy
Patients were immobilized in thermoplastic masks, ly-
ing on the back, with a comfortably filled urinary bladder 
(1.5–2 h after micturition).
CT was used for radiotherapy treatment planning and, 
in justified cases, PET-CT or additionally MRI. Treatment 
planning was conducted in the ARIA system, with scans re-
constructed every 3 mm. Contouring of the target volumes 
was performed according to the following principles: CTV- 
prostate, CTV-N+ involved lymph nodes, CTV-N elective 
pelvic lymph nodes, from common iliac lymph nodes to the 
obturator foramens. The PTV was defined by adding 6–10 
mm around the CTV. The radiation dose was specified in the 
isocenter. Conventional fractionation was used. The total 
dose in the prostate gland was 76 Gy, while in the involved 
lymph nodes it ranged from 60 to 76 Gy. All patients at the 
first stage of radiotherapy had elective irradiation of pelvic 
lymph nodes to a total dose of 44–5 0 Gy. Patients were irra-
diated using 6 or 20 MV photon beam with linear accelerator 
(19 patients) or tomotherapy (3 patients). 3D conformal 
techniques — 2 patients, or dynamic techniques (IMRT, 
RapidArc, tomotherapy) — 20 patients, were performed.
Table I . Clinical characteristics of the study group
Factor Number of patients
T tumor characteristics
T1c 4
T2a 2
T2b 2
T2c 5
T3a 4
T3b 3
T4 2
Gleason score
3 + 3 6
3 + 4 4
4 + 3 4
4 + 4 4
4 + 5 2
5 + 4 1
5 + 5 1
Number of nodes involved 
1 10
2 6
3 6
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Table II . Radiotherapy parameters
IGRT verification method
Bones 6
Prostate marker 13
RT technique
3DCRT 2
IMRT/RapidArc/tomotherapy 20
Total dose pelvic lymph nodes
44 Gy 19
45 Gy 1
50 Gy 2
Total dose, lymph nodes involved (N+)
60 Gy 5
64–66 Gy 11
70–72 Gy 5
75.6 Gy 1
Total dose prostate
75.6 Gy 2
76 Gy 18
78 Gy 2
IGRT in 2D-2D KV system was used in all patients treated 
with the accelerator. Verification was performed to the bo-
nes in 6 patients and to the gold marker implanted in the 
prostate in 13 patients. In the case of three patients treated 
with tomotherapy, a verification with tomography was per-
formed. Radiotherapy parameters are presented in Table I.
The evaluation of acute and late radiation morbidity 
was carried out by using the RTOG/EORTC scale. In addition, 
the local effect of treatment was assessed by using actuarial 
survival curves for local, regional and nodal control (N+). The 
Kaplan-Meier method was used for this purpose. As regards 
nodal control (N+), a complete remission, partial remission 
or stable disease were assumed to be a beneficial effect (i.e. 
nodal control).
For the global assessment of treatment efficacy, an ana-
lysis of actuarial biochemical control and overall survival (OS) 
was used. Following the definition provided by Phoenix, a 2 
ng/ml value above the PSA nadir was assumed to be a local 
failure. The evaluation of the impact of selected prognostic 
factors of treatment efficacy was conducted with the use 
of Cox proportional hazards model or logit regression. The 
value of p < 0.05 was considered statistically significant.
Results
The median follow-up period was 40 months. It was 
found that the 3-year and the estimated 5-year rates of 
local control were 86% and 86%, locoregional control was 
77% and 77%, distant metastases free survival were 76% 
and 76%. Due to the retrospective nature of the study and 
the fact that the majority of routine follow-up visits after 
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Table III. A list of 5 patients with failure after treatment
No T-stage Gleason Highest 
pre-RT PSA 
Type of failure Neoadj HT 
duration
Adjuvant HT 
duration
Number of nodes 
N+
Total 
dose N+
1 T2c 4 + 4 57.5 Biochemical recurrence 12 26 1 60
2 T4 3 + 4 31 Nodal dissemination(outside 
the boost N+ area)
9 31 1 70
3 T3a 3 + 3 58.2 Bone metastases 3 na 2 66
4 T2c 4 + 4 35.4 Nodal dissemination (outside 
the boost N+ area) + bone mets
3 28 1 66
5 T4 5 + 5 81.4 Nodal dissemination (outside 
the boost N+ area) + bone mets
6 12 3 66
Figure 1 . Biochemical control rate in the study group
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Figure 2 . Overall survival in the study group
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treatment was based primarily on PSA evaluation, no early 
radiological assessment after treatment was performed in 
50% of patients, which is why there was no possibility of 
conducting a reliable analysis of the early local response to 
radiotherapy. After radiotherapy, a 3-year and estimated 
5-year biochemical control in the study group amounted to 
78% and 65% respectively. The 3- and 5-year overall survival 
(OS) amounted to 88% and 73%. 5 treatment failures are 
presented in Table III.
Among patients with relapse, no progression in the 
irradiated, primarily involved lymph nodes (N+) was ob-
served. Among the analyzed factors: age, Gleason score, 
T-stage, number of involved lymph nodes, highest PSA level 
before oncological treatment, duration of neoadjuvant HT, 
duration of adjuvant HT — only the T-stage was associated 
with biochemical control (Fig. 3).
No dose-effect relationship for biochemical reccurence 
was observed (p = 0.81, Fig. 4).The total radiation dose in the 
involved lymph nodes also did not affect the overall survival 
(p = 0.76). Other analyzed parameters of radiotherapy also 
did not increased the risk of biochemical failure. Due to the 
small number of events (deaths), no detailed analysis for 
overall survival was conducted.
One patient required a one week break in irradiation 
due to acute grade II radiation morbidity; other patients 
completed treatment without delay. Acute grade II mor-
bidity was observed in 18% of patients — from rectum 
and among 22% patients — from urinary tract. No acute 
grade III reactions were observed. Late grade II urinary tract 
morbidity occurred in one patient, and the one from the 
rectum in two patients.
Discussion
In the 1990s, the RTOG 85-31 study demonstrated a 
10-year overall survival of 49% in patients treated with ra-
diotherapy combined with ADT vs 39% in patients receiving 
only RT. Disease-specific mortality was 16% vs 22% for the 
RT arm, and local failure for the combined arm was 23% vs 
38% for RT arm [4]. It was one of several groundbreaking 
studies indicating the relevance of combined treatment, i.e. 
the addition of hormonal therapy to radical radiotherapy. 
The same study confirmed the need for hormonal therapy in 
patients with pathologically confirmed metastases in lymph 
nodes, who received adjuvant radiotherapy — differences 
in 5-year and 9-year progression-free survival were 54% and 
10% for the above treatment vs 33% and 4% for patients 
treated only with RT. Such considerations in a reverse si-
tuation may lead to a question whether hormonal therapy 
alone in patients with locally advanced prostate cancer also 
requires the addition of radiotherapy? It turns out that the 
answer is “yes”. Radiotherapy-induced activation of immune 
system as well as abscopal effect and the need for treating 
cancer’s primary tumor are widely studied subjects. One 
randomized study concerning this subject demonstrated 
an improvement in 10-year survival from 49% to 55% after 
radiotherapy. What is more, the benefit in the reduction of 
biochemical recurrences was spectacular — approx. 30% vs 
65%. It is worth mentioning fact is that those patients rece-
ived RT doses below 70 Gy on prostate, which is well below 
modern standards [8]. This may lead to a conclusion that 
radiotherapy has supra-additive affect with ADT. However, 
for patients with regional advancement (N+), such gene-
ralization of results may not be justified and fully credible. 
Nonetheless, there are some retrospective reports which 
also indicate the benefit of combination treatment in these 
subgroups of patients [9–11]. 
In meta-analysis, Chun Chieh Lin et al. compared 636 
cN+ patients treated with hormonal therapy alone and 
those treated with hormonal therapy in combination with 
radiotherapy – an approx. 50% benefit in overall survival in 
favor of the ADT + RT group was demonstrated [9]. Tward 
et al. by analyzing 1.100 N+ patients, received a 10-year CSS 
of 62.7% for patients treated with radiotherapy, vs 50.3% 
for patients without RT [10]. Similarly, Rusthoven et al. by 
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Figure 3 . The probability of biochemical relapse as a function of 
T-stage
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Figure 4 . The biochemical control rate (bCR) as a function of Total 
dose to involved (N+) nodes
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analyzing 796 cN+ patients showed a 10-year PCCS of 67% 
for patients treated with radiotherapy, vs 53% for patients 
who received only hormonal therapy [11]. Since all these 
studies are retrospective, the results should be interpreted 
with some caution. In the light of these studies, the results 
concerning our institute’s patients (5-year bNED-65%) are 
comparable. It should be noted, however, that no informa-
tion on the applied radiation doses and additional boost 
in involved lymph nodes is provided in the cited studies. 
This leads us to the conclusion that radiotherapy combined 
with hormonal therapy is a treatment method which allows 
for achieving a satisfactory percentage of overall and can-
cer-specific survivals in patients with prostate cancer cN+.
Surgery is also worth mentioning as another valuable 
treatment method [5] — Steuber in a group of 158 patients 
showed a 10-year progression-free survival of 61% for the 
group treated with prostatectomy combined with ADT vs 
31% for the group receiving only ADT. Adding surgery to 
multidisciplinary treatment also allows us to obtain pa-
thological verification of clinically suspicious lymph nodes. 
Adjuvant radiotherapy may also play a role as a complemen-
tary treatment to prostatectomy and adjuvant hormonal 
therapy. Abdollah et al. analyzed a group of 1.107 patients 
after prostatectomy with pN1 involvement. Among them, 
35% received adjuvant radiotherapy, which increased the 
cancer-dependent survival rate to 87%, in comparison to 
82% in patients receiving only hormonal therapy [12]. Simi-
larly, Briganti [13] by analyzing 703 postoperative patients 
with pN+ advancement, received a significantly higher 5- 
and 10-year survival in the group treated with radiotherapy 
and hormonal therapy, compared to the group treated only 
with adjuvant hormonal therapy (5-year 95% vs 88%, 10-year 
86% vs 70%). These results were better for both minor and 
massive nodal involvement.
It is worth noting that we found no correlation between 
increasing total radiation dose to the involved lymph nodes 
and the efficacy of treatment among our patients. However, 
a small number of assessed cases, the retrospective nature 
of the work and the fact that only clinical evaluation of 
the involved lymph nodes (N+) without histopathological 
verification was performed, does not allow a fully reliable 
assessment of the dose-effect relationship and encoura-
ges further exploration of this topic. However, it should be 
emphasized that for instance in colorectal cancer there are 
suggestions concerning a different radiation sensitivity of 
the metastases than of the primary tumor, where metastatic 
lymph nodes are characterized by higher radiation sensi-
tivity [14]. This might be potentially also true for prostate 
cancer. Of course, as long as the volume of these lymph 
nodes, and hence the number of clonogenic cells, does not 
exceed a certain level. This may explain the absence of the 
dose-effect relationship in the 60–75 Gy range, which was 
presented in this study, especially as there are empirical 
reports in the literature which confirm such observation 
for other cancers, such as cervical cancer [15, 16]. In those 
studies, total doses of  ≥ 54–55 Gy were effective in eradi-
cation of nodal metastases. 
If, however, there is a dose-effect relationship in that 
dose range, an escalation not only of the physical dose, but 
also its intensity and the use of radiation ablative effects 
(e.g. through hypofractionated stereotactic boost) may 
have a higher value. However, these considerations are of 
speculative nature and are not addressed in this paper. The 
fact is that the effectiveness of the response of metastatic 
nodes (N+) among our patients was high, and the distant 
spread and progression to non-boosted lymph nodes was 
the reason for failure of treatment. From the point of view 
of radiotherapy planning and the equipment capabilities 
of various radiotherapy centers, a radiation dose escalation 
in a standard-fractionated manner instead of a stereotactic 
boost appears to be a quite attractive method. Our study, as 
well as other reports, also indicate that this is a well-tolerated 
treatment [17].
Conclusions
Radical radiotherapy with a boost to the metastatic 
lymph nodes combined with ADT is an effective treatment. 
The lack of correlation between the dose in the involved 
lymph nodes and the effect of treatment may indicate a 
higher sensitivity of metastases to radiation in comparison 
to the primary tumor. The retrospective character of this 
analysis supports the need for randomized clinical trials of 
these issues.
Conflict of interests: none declared
Tomasz Krzysztofiak, MD, PhD
Maria Skłodowska-Curie Institute — Oncology Center 
Gliwice Branch
Brachytherapy Department
ul. Wybrzeże Armii Krajowej 15 
44-100 Gliwice, Poland
e-mail: tomasz.krzysztofiak@io.gliwice.pl
Received: 27 Dec 2018 
Accepted: 8 Feb 2019
References
1. Polish National Cancer Registry [Krajowy Rejestr Nowotworów] — 
statistics for 2015.
2. Di Muzio N, Fodor A, Berardi G, et al. Lymph nodal metastases: diagnosis 
and treatment. Nucl Med Mol Imaging 2012; 56 (5): 421–9.
3. Mohler J, Bahnson RR, Boston B, et al. NCCN clinical practice guidelines 
in oncology: prostate cancer. J Natl Compr Canc Netw 2018.
4. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant 
to definitive radiotherapy in prostate carcinoma-long-term results of 
phase III RTOG 85–31. Int J Radiat Oncol Biol Phys. 2005; 61 (5): 1285–90.
5. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or 
without long-term androgen suppression for prostate cancer with high 
metastatic risk: 10-year results of an EORTC randomised study. Lancet 
Oncol 2010; 11 (11): 1066–73. 
6. Steuber T,  Budäus L, Walz J, et al. Radical prostatectomy improves 
progression-free and cancer-specific survival in men with lymph 
305
node positive prostate cancer in the prostate specific antigen era: a 
confirmatory study. BJU Int 2011; 107 (11): 1755–61.
7. Schick U,  Jorcano S,  Nouet P. Androgen deprivation and high-dose 
radiotherapy for oligometastatic prostate cancer patients with less than 
five regional and/or distant metastases. Acta Oncologica 2013; 52 (8). 
8. Mason MD, Parulekar WR, Sydes MR. Final Report of the Intergroup 
Randomized Study of Combined Androgen-Deprivation Therapy Plus 
Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally 
Advanced Prostate Cancer. J Clin Oncol 2015; 33 (19): 2143–50. 
9. Lin CC,  Gray  PJ, Jemal  A, Efstathiou JA. Androgen Deprivation With 
or Without Radiation Therapy for Clinically Node-Positive Prostate 
Cancer. JNCI J 2015; 107 (7).
10. Tward JD,  Kokeny KE,  Shrieve DC. Radiation therapy for clinically 
node-positive prostate adenocarcinoma is correlated with improved 
overall and prostate cancer-specific survival. Pract Radiat Oncol 2013; 
3 (3): 234–40.
11. Rusthoven CG, Carlson JA, Waxweiler TV, et al. The Impact of Definitive 
Local Therapy for Lymph Node-Positive Prostate Cancer: A Popula-
tion-Based Study. Int J Radiat Oncol Biol Phys 2014; 88 (5): 1064–73.
12. Abdollah F, Karnes RJ, Suardi N, et al. Predicting survival of patients 
with node-positive prostate cancer following multimodal treatment. 
Eur Urol 2014; 65 (3), 554–62.
13. Briganti A,   Karnes RJ,  Da Pozzo LF,  et al. Combination of Adjuvant 
Hormonal and Radiation Therapy Significantly Prolongs Survival of 
Patients With pT2–4 pN+ Prostate Cancer: Results of a Matched Analysis. 
Eur Urol 2011; 59 (5): 832–40.
14. Ahmed KA,  Fulp WJ,  Berglund AE,  et al. Differences Between Colon 
Cancer Primaries and Metastases Using a Molecular Assay for Tumor 
Radiation Sensitivity Suggest Implications for Potential Oligometastatic 
SBRT Patient Selection. Int J Radiat Oncol Biol Phys 2015; 92 (4): 837–42.
15. Vargo JA,  Kim H,  Choi S,  et al. Extended field intensity modulated 
radiation therapy with concomitant boost for lymph node-positive 
cervical cancer: analysis of regional control and recurrence patterns 
in the positron emission tomography/computed tomography era. Int 
J Radiat Oncol Biol Phys 2014; 90 (5): 1091–8.
16. Rash DL,  Lee YC,  Kashefi A,  et al. Clinical response of pelvic and 
para-aortic lymphadenopathy to a radiation boost in the definitive 
management of locally advanced cervical cancer. Int J Radiat Oncol 
Biol Phys 2013; 87 (2): 317–22.
17. Engels B, Soete G, Tournel K, et al. Helical tomotherapy with simultane-
ous integrated boost for high-risk and lymph node-positive prostate 
cancer: early report on acute and late toxicity. Technol Cancer Res 
Treat 2009; 8 (5): 353–59.
